San Francisco, CA, United States of America

Wendell A Lim

This inventor holds 27 USPTO granted patents and 46 published patent applications, plus 2 CIPO patents and 12 EPO patents, primarily in Cancer Treatment. Top assignees: University of California, Princeton University, The Simons Foundation Inc.. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wendell A Lim. Retrieved from https://idiyas.com/inventor/wendell-a-lim

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 27 (Patent Applications = 46)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 12)

EPO Patents = 12 (Patent Applications = 32)

Average Co-Inventor Count = 3.4

ph-index = 6

Forward Citations = 162(Granted Patents)

Location History:

Oakland, CA (US) (2014)
San Francisco, CA (US) (2009 - 2024)

Company Filing History:

27 out of 16,048

University of California

The Simons Foundation Inc.

where one patent can have more than one assignee

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

Chimeric Antigen Receptor

Glioblastoma Treatment

Modular Polypeptide Libraries

Proteolytically Cleavable Polypeptides

Binding-Triggered Transcriptional Switches

Cancer Cell Targeting

MAPK Signaling

Protein Logic Gates

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12636345 - METHODS OF TREATING GLIOBLASTOMAS (2026-05-26),

2. 12466892 - Systems and methods for targeting cancer cells (2025-11-11),

3. 12460199 - Modular polypeptide libraries and methods of making and using same (2025-11-04),

4. 12371466 - Chimeric antigen receptor and methods of use thereof (2025-07-29),

5. 12358988 - Proteolytically cleavable chimeric polypeptides and methods of use thereof (2025-07-15),

6. 12161672 - Chimeric antigen receptor and methods of use thereof (2024-12-10),

7. 12144826 - Methods of treating EGFRvIII expressing glioblastomas (2024-11-19),

8. 12090170 - Methods of treating glioblastomas (2024-09-17),

9. 12065479 - Force sensor cleavage domain containing chimeric polypeptides and methods of use thereof (2024-08-20),

10. 11560561 - Modular polypeptide libraries and methods of making and using same (2023-01-24),

11. 11478510 - Chimeric antigen receptor and methods of use thereof (2022-10-25),

12. 11401332 - Proteolytically cleavable chimeric polypeptides and methods of use thereof (2022-08-02),

13. 11400116 - Systems and methods for targeting cancer cells (2022-08-02),

14. 11136562 - Conditionally active heterodimeric polypeptides and methods of use thereof (2021-10-05),

15. 10888581 - Chimeric antigen receptor and methods of use thereof (2021-01-12),

Title: The Innovative Mind of Wendell A Lim

Introduction: Wendell A Lim is a renowned inventor based in San Francisco, CA, known for his groundbreaking contributions to the field of biotechnology and molecular engineering.

Latest Patents: Wendell A Lim holds several patents in the areas of synthetic biology, cellular engineering, and immunotherapy, showcasing his continuous innovation and dedication to advancing scientific knowledge.

Career Highlights: With a distinguished career spanning over two decades, Wendell A Lim has held key positions at prestigious research institutions and universities, where he has led pioneering research projects that have revolutionized the understanding of cellular processes.

Collaborations: Throughout his career, Wendell A Lim has collaborated with leading scientists, researchers, and industry experts to develop cutting-edge technologies and solutions that have the potential to transform the healthcare and biotechnology sectors.

Conclusion: Wendell A Lim's passion for innovation and his relentless pursuit of scientific excellence have established him as a trailblazer in the field of biotechnology, inspiring future generations of inventors and researchers to push the boundaries of what is possible in the world of science and technology.

Profile summary based on public USPTO records.